The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ludewig, B.
Right arrow Articles by Zinkernagel, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ludewig, B.
Right arrow Articles by Zinkernagel, R. M.
The Journal of Immunology, 2001, 166: 3369-3376.
Copyright © 2001 by The American Association of Immunologists

Hypercholesterolemia Exacerbates Virus-Induced Immunopathologic Liver Disease Via Suppression of Antiviral Cytotoxic T Cell Responses1

Burkhard Ludewig2, Martin Jäggi, Tilman Dumrese, Karin Brduscha-Riem, Bernhard Odermatt, Hans Hengartner and Rolf M. Zinkernagel

Institute of Experimental Immunology, Department of Pathology, University Hospital Zurich, Zurich, Switzerland


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The immune system has to be optimally balanced to be highly effective against infections with cytopathic microbial pathogens and must guarantee efficient destruction of cells infected with noncytopathic agents while leaving the integrity of noninfected cells largely unaltered. We describe here the effects of genetically induced hypercholesterolemia on cellular immunity in apolipoprotein E (ApoE-/-) and low density lipoprotein receptor-deficient (LDLR-/-) mice during infection with the hepatotropic lymphocytic choriomeningitis virus WE strain. In both ApoE-/- and LDLR-/- mice hypercholesterolemia aggravated virus-induced immunopathologic liver disease. ApoE-/- mice exhibited a higher susceptibility to virus-induced immunopathology than LDLR-/- mice and usually succumbed to immunopathologic disease when infected with high doses of virus. Initial virus spread was not influenced by the hypercholesterolemia, whereas clearance of the virus from spleen and nonlymphoid organs, including liver, was delayed. Activation of antiviral CTL, measured by ex vivo cytotoxicity and IFN-{gamma} production, and recruitment of specific CTL into blood and liver were impaired in hypercholesterolemic mice, indicating that hypercholesterolemia had a significant suppressive effect on cellular immunity. Taken together, these data provide evidence that hypercholesterolemia suppresses antiviral immune responses, thereby changing the host-virus balance, and can increase susceptibility to acute or chronic and potentially lethal virus-induced immunopathologic disease. These findings impinge on our understanding of hypercholesterolemia as a disease parameter and may explain aspects of the frequent association of persistent pathogens with hypercholesterolemia-induced diseases, such as atherosclerosis.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Hypercholesterolemia is recognized as one of the main risk factors for atherosclerosis (1), with the sequence of cholesterol accumulation in the arterial wall, local inflammatory responses leading to recruitment and activation of macrophages and T cells, and, finally, development of fibrotic lesions involving proliferation of smooth muscle cells (2). In addition, cholesterol metabolism impacts at various points on the responsiveness of the immune system. For example, chronic hypercholesterolemia predisposes the microvasculature to intense leukocyte-endothelial cell adhesion in response to inflammatory stimuli (3). Furthermore, modified LDL increases macrophage chemotaxis (4) and may stimulate T cells in atheromatous lesions (5). However, high lipoprotein levels in plasma diminish systemic cytokine responses (6, 7). Furthermore, high plasma cholesterol levels can result in impaired antibacterial immune responses, as shown by the failure of genetically hypercholesterolemic apolipoprotein E (ApoE)3-deficient (ApoE-/-) mice to rapidly clear Listeria monocytogenes (8) or Klebsiella pneumoniae infection (9). Similarly, hypercholesterolemic mice lacking the low density lipoprotein receptor (LDLR-/-) are highly susceptible to disseminated Candida albicans infection (10). Thus, beside local stimulatory effects in vascular inflammatory responses, hypercholesterolemia may also exert negative effects on general immune responsiveness.

To be effective in the defense against pathogens, the immune system has to be maximally effective against cytopathic infections, but may be only optimally balanced against poorly or noncytopathic agents. For example, cells infected with noncytopathic virus should be destroyed rapidly enough to prevent excessive immunopathology and to keep damage of noninfected cells at a minimum. Therefore, factors altering the equilibrium between the spread of poorly or noncytopathic pathogens and the immune response may favor acute or chronic immunopathologic disease. A well-studied model of virus-induced immunopathology is the infection with the lymphocytic choriomeningitis virus (LCMV) (11, 12). Immunopathologic disease in acute LCMV infection is primarily mediated by CTL, which may cause the classical choriomeningitis after intracerebral infection when meningeal cells become targets for the antiviral immune response (13), hepatitis after infection with hepatotropic strains (14), or immunosuppression when APCs in the lymphoid tissues are destroyed (15). The importance of CTL in LCMV-induced immunopathology also has been demonstrated in transgenic mice expressing the LCMV glycoprotein in the islets of Langerhans (16, 17) where contact-dependent, perforin-mediated lysis of viral Ag-expressing cells is crucial to mediate the immunopathologic response (18). The extent of LCMV-induced immunopathologic disease depends on various host and virus parameters, such as viral tropism (14, 19), genetic background (19, 20), and immunocompetence of the host (21).

Thus, LCMV infection offers an experimental system to thoroughly investigate the influence of additional potential disease parameters such as hypercholesterolemia. We used here ApoE-/- and LDLR-/- mice to determine whether these factors alter virus-host equilibrium and enhance or prevent immunopathologic disease. Mice were infected with the hepatotropic LCMV WE strain, which can lead to substantial CTL-mediated liver cell damage in a dose-, age-, and MHC-dependent fashion (14, 20). Using MHC class I tetramers complexed with defined viral epitopes (22, 23), we followed activation and peripheral recruitment of virus-specific CTL. In addition, antiviral T cell effector function was followed by cytotoxicity and cytokine production assays. The results show that hypercholesterolemia may lead to a substantial impairment of antiviral cellular immune responses, leading to delayed viral clearance from spleen and nonlymphoid organs. As a consequence of the disturbed virus-host equilibrium, mice developed severe immunopathologic disease.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

C57BL/6 mice were obtained from the Institut für Labortierkunde (University of Zurich, Zurich, Switzerland). ApoE-/- mice (24) and LDLR-/- mice (25), both on a C57BL/6J background, were obtained from The Jackson Laboratory (Bar Harbor, ME). Animals were fed normal rodent chow (ND, Provimi Kliba, Kaiserangst, Switzerland), or high cholesterol diet (HCD, ND supplement with 1.25% cholesterol, 8% fat, Provimi Kliba). All animals were kept under specific pathogen-free conditions. Experiments were conducted with age-matched (6–8 wk) and sex-matched animals. The animal protection law of the Kanton of Zurich (Zurich, Switzerland) limits the number of mice to be used in experiments, particularly if disease is severe and potentially lethal. Therefore, experiments generally were repeated twice with groups of three to five mice.

Viruses, cell lines, and peptides

LCMV-WE was originally obtained from Dr. F. Lehmann-Grube (Hamburg, Germany) and was propagated on L929 cells. EL-4 (H-2b), a thymoma cell line, was used as the target cell. LCMV-GP peptides KAVYNFATM (GP33) and FQPQNGQFI (NP396) were purchased from Neosystem Laboratoire (Strasbourg, France).

Cytotoxicity assay

For detection of primary ex vivo cytotoxicity, effector cell suspensions were prepared from spleen or liver of infected mice on day 7 or 9 after infection. EL-4 cells were pulsed with LCMV GP33 or NP396 (10-6 M, 1.5 h at 37°C) and used in a standard 5-h 51Cr release assay. Unlabeled EL-4 cells served as controls. The supernatant of the cytotoxicity cultures was counted in a Cobra II Gamma Counter (Canberra Packard, Downers Grove, IL). Spontaneous release was always <20%.

Construction of tetrameric MHC class I-peptide complexes

MHC class I (H2-Db) tetramers complexed with GP33 or NP396 were produced as previously described (22). Briefly, H2-Db and human {beta}2-microglobulin molecules were recombinantly expressed in Escherichia coli (the plasmids were provided by John Altman, Emory University, Atlanta, GA). Biotinylated H2-Db peptide complexes were purified using an Aekta Explorer 10 chromatography system (Pharmacia, Uppsala, Sweden) and tetramerized by addition of streptavidin-PE (Molecular Probes, Eugene, OR).

Intracellular cytokine staining

To determine the number of IFN-{gamma}-producing cells, single-cell suspensions were prepared from liver or spleen by gently pressing the organs through a stainless steel grid. Liver cell suspensions were underlaid with Ficoll separating solution (Biochrom KG, Berlin, Germany) and spun at 2500 rpm for 20 min. The cells from the interface were washed twice and resuspended in PBS/2% FCS/0.5 mM EDTA (FACS buffer). Lymphocytes (106) from spleen or liver were left untreated, stimulated with LCMV peptides (10-7 M), or treated with PMA (10 ng/ml; Sigma, St. Louis, MO) and ionomycin (500 ng/ml; Sigma) for 6 h at 37°C. Brefeldin A (12.5 ng/ml; Sigma) was added for the duration of the culture to facilitate intracellular accumulation of the cytokine. Cells were first stained with PE-labeled anti-CD8 (PharMingen, San Diego, CA) at 4°C, followed by fixation with 4% paraformaldehyde in PBS for 20 min. Cells were permeabilized using saponin buffer (PBS/2% FCS, 5 mM EDTA, and 0.1% saponin) and stained with anti-IFN-{gamma}-FITC (PharMingen).

Flow cytometry and tetramer staining

On day 7 postinfection with 200 PFU of LCMV, single-cell suspensions were prepared from liver or spleen, and aliquots of 5 x 105 cells or three drops of blood were stained using 50 µl of a solution containing tetrameric class I-peptide complexes at 37°C for 10 min, followed by staining with anti-CD8-FITC (PharMingen) at 4°C for 20 min. Erythrocytes in blood samples were lysed with FACS lysis solution (Becton Dickinson, Mountain View, CA), and cells were analyzed on a FACScan flow cytometer (Becton Dickinson) after gating on viable lymphocytes.

Viral titers

C57BL/6, ApoE-/-, or LDLR-/- mice were infected i.v. with the hepatotropic LCMV strain WE. Virus titers in spleen, kidney, liver, and lung were determined at the indicated time points in an LCMV infectious focus assay as previously described (26). Values of virus titers in the various organs are expressed as log10 PFU per gram. Statistical analysis was performed using Prism 2.01 software (GraphPad Software, Berkeley, CA).

Immunohistology

Freshly removed organs were immersed in HBSS and snap-frozen in liquid nitrogen. Tissue sections of 5-µm thickness were cut in a cryostat and fixed in acetone for 10 min. Sections were incubated with anti-mouse CD8+ cells mAb (YTS169.4.2) (27) or rat anti-LCMV-NP mAb (VL-4) (26). Alkaline phosphatase-labeled, species-specific goat Abs (Tago, Burlingame, CA) were used as secondary reagents. The substrate for the red color reaction was AS-BI phosphate/New Fuchsin. Sections were counterstained with hemalum.

Assay of serum TNF

TNF concentrations were determined by solid phase ELISA (BioSource, Camarillo, CA) according to the manufacturer’s instructions. Samples were stored at -20°C and analyzed in a single assay.

Determination of serum enzyme concentrations

Assays for serum concentrations of alanine aminotransferase (ALT), aspartate aminotransferase, and total cholesterol in plasma were performed at the Department of Clinical Chemistry, University Hospital Zurich, using photometric assays on a Hitachi 747 autoanalyzer (Tokyo, Japan).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Hypercholesterolemia exacerbates virus-induced immunopathologic liver disease

Infection of C57BL/6 mice with low doses (2 x 102 PFU) of LCMV WE induces a mild inflammation in the liver without measurable increase of liver enzymes in serum, whereas infection with high doses (>105 PFU) leads to a strong, but transient, increase in liver enzymes in serum (14). Infection of ApoE-/- mice with 200 PFU of LCMV (low dose) elicited an increase in liver enzymes compared with levels in C57BL/6 control mice (Fig. 1GoA). The increased release of liver enzymes was diet-independent, since ApoE-/- mice fed a normal chow diet (ND) and those fed a high cholesterol diet (HCD) showed comparable elevations of liver enzymes in serum despite dramatic differences in plasma cholesterol values (Fig. 1GoA). After high dose infection (2 x 105 PFU), both hypercholesterolemic ApoE-/- and C57BL/6 mice developed fulminant hepatitis (Fig. 1GoB). ApoE-/- mice fed HCD and infected with a high dose died before day 12 (Fig. 1GoB). Statistical analysis of the data revealed that liver enzyme values were significantly elevated on day 8 after low dose infection (Fig. 1GoC), whereas the values on day 8 after high dose infection were not significantly different (not shown). Cholesterol levels on day 12 were elevated after low dose infection in ApoE-/- mice (Fig. 1GoA) and in ApoE-/- and C57BL/6 mice infected with a high dose of LCMV (Fig. 1GoB). Prolongation of HCD exacerbated the liver disease after LCMV infection and caused >50% mortality after 6 wk of HCD (Fig. 1GoD). Immunopathologic disease was most severe in ApoE-/- mice fed HCD and infected with a high dose of LCMV, with an overall mortality of 80% (Fig. 2Go). In contrast, HCD-fed C57BL/6 mice infected with a high dose were not susceptible, and ApoE-/- mice infected with a low dose were less susceptible to lethal immunopathologic disease (Fig. 2Go).



View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 1. Kinetics, virus dose, and cholesterol dependence of the changes in liver enzyme concentrations in serum of LCMV-WE-infected ApoE-/- and control mice. Mice were infected i.v. with 200 PFU of LCMV (low dose; A) or 2 x 105 PFU of LCMV (high dose; B) on day 0 and bled at the indicated time points, and liver enzyme levels in serum and plasma cholesterol concentrations were determined. Mice were fed ND or HCD from the day of infection. Values are the mean ± SD of three to five mice per group. C, Statistical analysis (Mann-Whitney test) of cumulated day 8 values from two independent experiments revealed significant differences in liver enzyme release between ApoE-/- and control C57BL/6 mice. D, Influence of long term HCD on LCMV-induced immunopathologic liver disease. ApoE-/- and C57BL/6 mice were fed HCD for 3 or 6 wk and then infected with 200 PFU of LCMV. Data points represent ALT values on day 8 postinfection of single mice; mean values are indicated by the horizontal bars. Five of nine 6-wk HCD-fed ApoE-/- mice died between days 7 and 8 postinfection. ALT values for uninfected mice after 6 wk of HCD: ApoE-/-, 51 ± 21; C57BL/6, 36 ± 5.

 


View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 2. Survival of ApoE-/- and control mice after LCMV infection. ApoE-/- (n = 10; dotted line) or C57BL/6 mice (n = 10; solid line) infected i.v. with 2 x 105 PFU of LCMV or ApoE-/- mice infected with 200 PFU of LCMV (n = 8; dashed line) were fed HCD, and survival was monitored for 20 days. Data are pooled results from two independent experiments.

 
LDLR-/- mice exhibit less severe alterations in cholesterol metabolism compared with ApoE-/- mice (28). In LDLR-/- mice, liver enzyme values were increased after low dose infection with LCMV (Fig. 3GoA), whereas strong immunopathology developed in both LDLR-/- and wild-type mice after high dose infection (Fig. 3GoB). However, the disease-enhancing effect of hypercholesterolemia in LDLR-/- mice only became obvious when mice were fed HCD; low dose infection of LDLR-/- on ND did not induce increased liver enzyme values in the serum (Fig. 3GoC). Infection raised cholesterol levels in plasma of LDLR-/- mice after both low dose (Fig. 3GoA) and high dose (Fig. 3GoB) infection. In contrast to ApoE-/- mice, LDLR-/- mice did not succumb to immunopathologic disease, even when the HCD was fed for >6 wk (not shown). Taken together, LCMV infection revealed the close correlation between the severity of hypercholesterolemia and the susceptibility to virus-induced immunopathology: normocholesterolemic C57BL/6 mice were not affected after low dose infection, LDLR-/- mice showed severe immunopathology only when fed HCD, and ApoE-/- mice, displaying the most profound defect in cholesterol metabolism, were highly susceptible to virus-induced immunopathology and succumbed to high dose infection when fed HCD.



View larger version (32K):
[in this window]
[in a new window]
  		FIGURE 3. Kinetics and virus dose dependence of liver enzymes in serum of LDLR-/- mice. Mice were infected i.v. with 200 PFU of LCMV (low dose; A) or 2 x 105 PFU of LCMV (high dose; B) on day 0 and bled at the indicated time points, and liver enzyme levels in serum and plasma cholesterol concentrations were determined. All mice were fed HCD. Values are the mean ± SD of three or four mice per group. C, Statistical analysis (Mann-Whitney test) of cumulated ALT values from C57BL/6 mice fed HCD, LDLR-/- fed ND, and LDLR-/- fed HCD after low dose LCMV infection. Data points represent ALT values on day 8 postinfection of individual mice; mean values are indicated by horizontal bars.

 
Impaired virus clearance in hypercholesterolemic mice

In essence, there are two possible scenarios to explain the above findings. First, nonspecific resistance and specific immune responses in hypercholesterolemic mice might be increased, leading to a more vigorous antiviral response with more "bystander" damage. In particular, TNF, which has been shown to be up-regulated after infection of hypercholesterolemic mice with bacteria (8, 9) or C. albicans (10), may mediate such pathological effects. To address this first possibility, serum TNF values were determined after infection with 200 PFU of LCMV in ApoE-/-, LDLR-/-, and C57BL/6 control mice fed either ND or HCD. In contrast to the enhanced TNF production in hypercholesterolemic mice after infection with bacteria (8, 9) or C. albicans (10), TNF concentrations in serum of LCMV-infected normo- and hypercholesterolemic mice were below the limits of detection (<5 pg/ml; data not shown). This suggested that excessive TNF production in hypercholesterolemic mice is unlikely to contribute importantly to the exacerbated virus-induced immunopathology.

The second explanation is that impairment of virus-specific immune responses in hypercholesterolemic mice may cause an imbalance between virus control vs immunopathologic damage. We therefore followed the initial viral spread and determined the clearance of LCMV from spleen and nonlymphoid tissues. Initial virus distribution (day 4 postinfection) was not affected by the hypercholesterolemia, and comparable levels of infectious virus were found in spleen (Table IGo) and other organs (liver, lung, and kidney; data not shown). On day 7 postinfection, however, viral loads were slightly elevated in spleen and liver of ApoE-/- and LDLR-/- mice compared with those in C57BL/6 controls. Increasing the hypercholesterolemia by HCD further impaired the clearance of the virus, particularly in ApoE-/- mice (Table IGo).


View this table:
[in this window]
[in a new window]
  		Table I. Virus titers in organs of ApoE-/-, LDLR-/-, and C57BL/6 mice after LCMV infectiona

 
To test the effect of long-lasting elevated plasma cholesterol levels on virus clearance from liver and spleen, ApoE-/- and C57BL/6 mice were fed HCD for 6 wk and then infected with 200 PFU of LCMV. The presence of viral Ag in liver and spleen was assessed on day 9 postinfection using a sensitive immunohistochemical method and correlated with antiviral CTL activity in spleen. After long term HCD feeding, large numbers of CTL were found in livers of C57BL/6 mice (Fig. 4GoA), and virus was cleared from liver (Fig. 4GoB) and spleen (not shown). CTL activity in spleen (Fig. 4GoC) was comparable to that in C57BL/6 mice fed ND (not shown). CTL infiltration in livers of ApoE-/- mice fed HCD from the day of infection (Fig. 4GoD) was high, whereas ApoE-/- mice fed HCD for 6 wk showed a strong decrease in liver-infiltrating CTL (Fig. 4GoG). Furthermore, the failure of both short term (Fig. 4GoE) and long term (Fig. 4GoH) HCD-fed ApoE-/- mice to completely clear LCMV Ag from the liver correlated well with a progressive loss of CTL activity in spleens after short term (Fig. 4GoF) and long term (Fig. 4GoI) HCD. These findings suggest that the hypercholesterolemia in ApoE-/- and LDLR-/- mice had a negative impact on the virus-host balance, leading to delayed clearance of the virus.



View larger version (122K):
[in this window]
[in a new window]
  		FIGURE 4. Presence of CD8+ T cells and LCMV Ag in liver of ApoE-/- and C57BL/6 mice. C57BL/6 fed HCD for 6 wk (A–C), ApoE-/- (D–F), or ApoE-/- fed HCD for 6 wk (G–I) were infected i.v. with 200 PFU of LCMV. All mice received HCD until day 9 postinfection, and the presence of CD8 T cells (A, D, and G) and LCMV Ag (B, E, and H) in livers was evaluated by immunohistochemistry. Direct ex vivo CTL activity of spleen cells was tested on 51Cr-labeled EL4 cells pulsed with GP33 ({blacksquare}) or NP396 ({blacktriangleup}; C, F, and I). Unpulsed 51Cr-labeled EL4 served as controls ({square}). Values are the mean ± SD of three or four mice per group. Results from one representative of two experiments are shown.

 
Altered antiviral CTL responses in hypercholesterolemic mice

To evaluate the antiviral immune response in hypercholesterolemic mice more thoroughly, we first used MHC class I tetramers to detect and enumerate virus-specific CTL in blood, spleen, and liver. Cells were stained with H2-Db (GP33) tetramers, and the percentage of CD8 lymphocytes positive for GP33 tetramers was calculated. In livers of ApoE-/- mice, 7.1 ± 0.4% of the CD8 T cells were specific for GP33 on day 7 postinfection (Fig. 5GoA). Values for LDLR-/- (Fig. 5GoB) and C57BL/6 control mice (Fig. 5GoC) were always higher. Statistical analysis of all mice tested revealed that ApoE-/- mice fed either ND or HCD suffered from significantly impaired activation of virus-specific CTL in the spleen and reduced recruitment of antiviral CTL into blood and liver (Fig. 5GoD). CTL activation in LDLR-/- mice after LCMV infection was only slightly reduced, and alterations were significant only for blood values after HCD feeding (Fig. 5GoD). Examination of the cytotoxicity of liver-infiltrating CTL by comparison of the E:T cell ratios for the 33% lysis revealed a 3- to 5-fold reduction of the relative CTL activity in ApoE-/- mice compared with that in control C57BL/6 mice that may be partially due to the differences in the frequencies of GP33- or NP396-specific CTL in the cytotoxicity assay. Liver-infiltrating CTL in LDLR-/- mice were less affected (Fig. 5GoE). No clear effect of the diet on relative CTL activity within one strain of mice was observed (compare left and right columns in Fig. 5GoE).



View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 5. CTL activation and recruitment into blood and liver in hypercholesterolemic and control mice after LCMV infection. ApoE-/-, LDLR-/-, or C57BL/6 mice fed either ND or HCD were infected i.v. with 200 PFU of LCMV. Seven days later, GP33-specific CD8+ T cells in liver, spleen, and blood were visualized using MHC class I tetramers. Representative FACS stainings from liver of ND-fed ApoE-/- (A), LDLR-/- (B), and C57BL/6 (C) mice are shown. The mean percentage of CD8 T cells specific for GP33 (±SEM) is indicated in the corresponding upper right quadrant. D, Mean percentages ± SEM of tetramer-GP33-positive CD8+ T cells in spleen, liver, and blood of the indicated mouse strains. Pooled data from two independent experiments are shown. Statistically significant differences (p < 0.05, by Mann-Whitney test) between hypercholesterolemic ApoE-/- or LDLR-/- and C57BL/6 mice are indicated by an asterisk. E, Ex vivo CTL activity of pooled liver-infiltrating lymphocytes on day 7 postinfection. 51Cr-labeled, GP33-pulsed ({blacksquare}), NP396-pulsed ({blacktriangleup}), or unpulsed ({square}) EL4 cells were used as target cells. The dashed line indicates 33% specific lysis.

 
IFN-{gamma} is important for the control of LCMV infection (29, 30) and may contribute to the elimination of LCMV from hepatocytes by noncytolytic mechanisms (31). We therefore assessed the production of IFN-{gamma} in virus-specific CTL in spleen of HCD fed ApoE-/- (Fig. 6Go, A and B), LDLR-/- (Fig. 6Go, C and D), and C57BL/6 control mice (Fig. 6Go, E and F) on day 7 after infection with LCMV. Freshly isolated splenic lymphocytes from C57BL/6 mice produced significant amounts of IFN-{gamma} after 6 h of restimulation in vitro with GP33 (Fig. 6GoE) or NP396 (Fig. 6GoF). IFN-{gamma} production of virus-specific CD8 T cells from LDLR-/- was reduced (Fig. 6Go, E and D). In ApoE-/- mice, again, the impairment of antiviral CTL responses was most severe (Fig. 6Go, A and B). Taken together, the activation of virus-specific CTL was severely affected in hypercholesterolemic mice, suggesting that viral clearance from spleens and nonlymphoid organs in hypercholesterolemic mice was impaired because hypercholesterolemia-induced immunosuppression inhibited the generation of a sufficient antiviral CTL response.



View larger version (45K):
[in this window]
[in a new window]
  		FIGURE 6. IFN-{gamma} production of LCMV-specific CD8+ T cells in hypercholesterolemic ApoE-/- and LDLR-/- mice. ApoE-/- (A and B), LDLR-/- (C and D), or C57BL/6 (E and F) mice fed HCD were infected i.v. with 200 PFU of LCMV. On day 7 post infection, splenocytes and liver-infiltrating lymphocytes were restimulated with LCMV peptides GP33 or NP396 in vitro, and specific IFN-{gamma}-producing CD8 T cells were detected by intracellular cytokine staining. Mean percentages (± SEM) of IFN-{gamma}-producing CD8 T cells in spleen and liver of the indicated mouse strains are shown in the upper right quadrant of the respective histograms. Four mice per group were analyzed. One of two comparable experiments is shown.

 
Impaired antiviral memory responses in hypercholesterolemic mice

The maintenance of high precursor frequencies and efficient reactivation of CTL are important to confer antiviral protection after re-encounter with virus (32, 33). Maximal expansion of virus-specific CTL after LCMV infection is reached around day 8, followed by a continuous decrease until day 30, when a stable memory population with elevated precursor frequencies is established (34, 35). To determine whether the hypercholesterolemia-induced reduction of immune responsiveness also affected LCMV-specific memory responses, mice infected 30 days previously with LCMV were challenged with a high dose of LCMV, and MHC class I tetramers were used to visualize Ag-specific CD8+ T cells (Fig. 7Go). Expansion of GP33- and NP396-specific CTL in spleen on day 4 after LCMV challenge infection was reduced in ApoE-/- (Fig. 7Go, A and B) and LDLR-/- mice (Fig. 7Go, C and D) compared with that in C57BL/6 control mice (Fig. 7Go, E and F). Thus, antiviral cellular immunity in ApoE-/- and LDLR-/- mice was impaired in both acute and memory anti-LCMV responses.



View larger version (53K):
[in this window]
[in a new window]
  		FIGURE 7. Virus-specific CD8 T cell memory responses in hypercholesterolemic mice. ApoE-/- (A and B), LDLR-/- (C and D), or C57BL/6 (E and F) mice infected 30 days previously with a low dose of LCMV were challenged with 2 x 105 PFU of LCMV. Four days after the challenge infection, the percentage of GP33-specific (A, C, and E) and NP396-specific (B, D, and F) CD8 T cells in spleens were determined by tetramer staining. Mean percentages (± SEM) of specific tetramer-positive CD8 T cells are shown in the upper right quadrant of the respective histograms. Three or four mice per group were analyzed. One of two experiments is shown.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In the course of an antiviral immune response a well-balanced equilibrium between virus spread and antiviral effector mechanisms is usually established. The major finding of this study is that hypercholesterolemia can disrupt this equilibrium and enhance severe immunopathology after infection with a hepatropic noncytopathic virus. Although the role of hypercholesterolemia in the pathogenesis of atherosclerosis has been studied extensively in ApoE-/- and LDLR-/- mice (36, 37, 38, 39), a thorough analysis of T cell reactivity in these mice in response to a viral infection has not been previously described. This is particularly important since viral infections (40, 41) and antiviral immune reactions in the vascular wall (42, 43) are thought to crucially contribute to vascular immunopathology. Our studies documenting the impairment of antiviral T cell immunity in genetically hypercholesterolemic mice impinge on our understanding of hypercholesterolemia as a cofactor in immunopathologic disease. In view of the fact that atherosclerosis can be defined at least partially as an immunopathologic vascular disease (43), our findings may explain the mechanism of how particular infectious agents may participate in establishment and maintenance of atherosclerotic disease.

This study extends and complements previous studies on the susceptibility of hypercholesterolemic mice to infectious pathogens. Successful immune responses against fast replicating, cytopathic infectious agents depend mainly on innate immune mechanisms, such as type I IFN (29), or complement (44, 45). The high susceptibility of LDLR-/- mice to generalized Candidiasis (10) and of ApoE-/- mice to L. monocytogenes (8) and Klebsiella infection (9) suggests that hypercholesterolemia leads to an impairment of innate immune responses. In noncytopathic LCMV infection, innate immune responses contribute to limit the initial spread of the virus and therefore limit or prevent immunopathologic disease or exhaustion (46). However, in the present study we could not detect differences in the initial spread of LCMV in hypercholesterolemic ApoE-/- or LDLR-/- mice vs wild-type controls, suggesting that innate control of LCMV was not affected significantly by the defect in cholesterol metabolism. Furthermore, we could not detect massive TNF production as had been observed in the bacterial (8, 9) or fungal infections (10) of hypercholesterolemic mice, supporting the idea that LCMV may trigger TNF production only to a limited extent.

Viruses or other micro-organisms with a low cytopathicity often establish persisting infections in varying host-pathogen balances that permit the survival of both host and pathogen. However, the immunopathologic consequences of the immune response, for example against LCMV, critically depend on both virus distribution and kinetics of the T cell response. The wider the virus spreads and the longer it persists, the more serious are the pathological consequences of the antiviral immune response, unless in an extreme situation, T cells are exhausted (47). Furthermore, defects in cellular immunity, such as perforin deficiency, favor LCMV persistence and may lead to increased immunopathologic disease generally and in the bone marrow (48). The data of this study indicate that the anti-LCMV response in hypercholesterolemic mice may be too weak to eliminate the virus efficiently from infected hepatocytes and other peripheral tissues, but is sufficiently strong to elicit substantial immunopathology. Since virus replication seemed little affected by the hypercholesterolemia, effects on T cell responsiveness in the induction and/or effector phase are suggested. It is possible that alterations in membrane cholesterol composition may influence T cell reactivity, as suggested by early in vitro studies by Cerottini and colleagues (49). Similar processes may also influence immune responses against noncytopathic and ubiquitous pathogens frequently associated with hypercholesterolemia. Indeed, Chlamydia pneumoniae is efficiently controlled in normocholesterolemic and immunocompetent C57BL/6 mice, but spreads more widely and infects newly formed atheromatous lesions in hypercholesterolemic ApoE-/- mice (50). Similar findings have been reported for LDLR-/- mice, where the pathogenic, atherosclerosis enhancing effect of C. pneumoniae became apparent only after nine mo on a high cholesterol diet (51). Furthermore, it is striking that CMV induce immunopathologic vascular disease exclusively in immunocompromised hosts; e.g. only irradiated mice (52) or rats (53) develop severe arterial inflammation after infection with murine or rat CMV, respectively. In addition, mice lacking the IFN-{gamma} receptor are more susceptible to infection with murine CMV (54) or gammaherpesvirus 68 (55) and develop progressive chronic arterial inflammation. It is therefore likely that the frequent association of human CMV infection with atherosclerotic disease (56, 57) is due at least in part to immunosuppression. Long-lasting hypercholesterolemia might, as shown in this report, mediate such defects in cellular immunity and therefore favor development of immunopathologic disease. Importantly, infection with herpesviruses (52, 58) and acute LCMV infection, as shown here, can further alter cholesterol metabolism. Thus, self-perpetuating immunopathologic disease circuits may develop when chronic hypercholesterolemia-mediated immunosuppression impairs the usually well-balanced host-pathogen equilibrium.

It will be important to further elucidate the mechanisms underlying the hypercholesterolemia-mediated defects in innate and adaptive immunity observed in this and previous reports (8, 9, 10). An important link between innate and adaptive immunity is provided by macrophages rapidly producing large amounts of effector molecules upon encounter with pathogens (59). Since macrophages are critically involved in cholesterol metabolism (60), it is likely that chronic hypercholesterolemia leads to pre- and/or overstimulation of macrophages. This could explain the elevated TNF responses of hypercholesterolemic mice in response to bacterial and fungal pathogens (8, 9, 10). In LCMV infection, the integrity of the macrophage system and its appropriate activation is of prime importance for efficient control of the pathogen (61). It is therefore possible that metabolic distress due to hypercholesterolemia may cause macrophage alterations and may inhibit Ag presentation leading to impaired induction of specific T cells. Furthermore, hypercholesterolemia may alter the microenvironment between APC and T cells leading to preferential Th2 differentiation (62) and may thereby impair generation of efficient antiviral CTL responses. Alternatively, but not mutually exclusive, cellular membrane characteristics may be altered in hypercholesterolemic mice, leading to changes in the functionality of membrane domains containing glycosphingolipids and cholesterol, called lipid rafts (63). In resting and activated T cells, membrane-protein interactions and TCR signaling critically depend on the integrity of cholesterol-containing lipid rafts (64). It is therefore possible that the observed reduced T cell reactivity in hypercholesterolemic mice is at least in part due to impaired TCR-associated signaling pathways.

In summary, using a well-characterized model of virus-induced immunopathology, we assessed the influence of genetically induced hypercholesterolemia on antiviral CTL responses. Hypercholesterolemia was found to substantially impair antiviral T cell immunity, causing exacerbation of potentially lethal immunopathologic disease.


   Acknowledgments
 
We thank Kathy McCoy for helpful discussions and critical reading of the manuscript, Lenka Vlk and Anne Henzelin for expert technical assistance, and Norbert Wey and Ida Schmieder for excellent photographic work.


   Footnotes
 
1 This work was supported by the Swiss National Science Foundation and the Kanton Zurich. Back

2 Address correspondence and reprint requests to Dr. Burkhard Ludewig, Institute of Experimental Immunology, Department of Pathology, University of Zurich, Schmelz-bergstrasse 12, CH-8091 Zurich, Switzerland. Back

3 Abbreviations used in this paper: ApoE, apolipoprotein E; ApoE-/-, ApoE-deficient mice; LCMV, lymphocytic choriomeningitis virus; LDLR, low density lipoprotein receptor; LDLR-/-, LDLR-deficient mice; ND, normal chow diet; HCD, high cholesterol diet; ALT, alanine aminotransferase. Back

Received for publication September 15, 2000. Accepted for publication December 20, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Braunwald, E.. 1997. Shattuck lecture: cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N. Engl. J. Med. 337:1360.[Free Full Text]
  2. Ross, R.. 1999. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340:115.[Free Full Text]
  3. Henninger, D. D., M. E. Gerritsen, D. N. Granger. 1997. Low-density lipoprotein receptor knockout mice exhibit exaggerated microvascular responses to inflammatory stimuli. Circ. Res. 81:274.[Abstract/Free Full Text]
  4. Navab, M., S. S. Imes, S. Y. Hama, G. P. Hough, L. A. Ross, R. W. Bork, A. J. Valente, J. A. Berliner, D. C. Drinkwater, H. Laks. 1991. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88:2039.
  5. Stemme, S., B. Faber, J. Holm, O. Wiklund, J. L. Witztum, G. K. Hansson. 1995. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 92:3893.[Abstract/Free Full Text]
  6. Levine, D. M., T. S. Parker, T. M. Donnelly, A. Walsh, A. L. Rubin. 1993. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl. Acad. Sci. USA 90:12040.[Abstract/Free Full Text]
  7. Netea, M. G., P. N. Demacker, B. J. Kullberg, O. C. Boerman, I. Verschueren, A. F. Stalenhoef, J. W. van der Meer. 1996. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe Gram-negative infections. J. Clin. Invest. 97:1366.[Medline]
  8. Roselaar, S. E., A. Daugherty. 1998. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J. Lipid Res. 39:1740.[Abstract/Free Full Text]
  9. de Bont, N., M. G. Netea, P. N. Demacker, I. Verschueren, B. J. Kullberg, K. W. van Dijk, J. W. van der Meer, A. F. Stalenhoef. 1999. Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J. Lipid Res. 40:680.[Abstract/Free Full Text]
  10. Netea, M. G., P. N. Demacker, N. de Bont, O. C. Boerman, A. F. Stalenhoef, J. W. van der Meer, B. J. Kullberg. 1997. Hyperlipoproteinemia enhances susceptibility to acute disseminated Candida albicans infection in low-density-lipoprotein-receptor-deficient mice. Infect. Immun. 65:2663.[Abstract]
  11. Buchmeier, M. J., R. M. Welsh, F. J. Dutko, M. B. Oldstone. 1980. The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv. Immunol. 30:275.[Medline]
  12. Zinkernagel, R. M.. 1997. Virus-induced immunopathology. N. Nathanson, and R. Ahmed, and F. Gonzalez-Scarano, eds. Viral Pathogenesis 163.-180. Lippincott-Raven, Philadelphia.
  13. Cole, G. A., N. Nathanson, R. A. Prendergast. 1972. Requirement for theta-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease. Nature 238:335.[Medline]
  14. Zinkernagel, R. M., E. Haenseler, T. Leist, A. Cerny, H. Hengartner, A. Althage. 1986. T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus: liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay?. J. Exp. Med. 164:1075.[Abstract/Free Full Text]
  15. Odermatt, B., M. Eppler, T. P. Leist, H. Hengartner, R. M. Zinkernagel. 1991. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. Proc. Natl. Acad. Sci. USA 88:8252.[Abstract/Free Full Text]
  16. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malissen, R. M. Zinkernagel, H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305.[Medline]
  17. Oldstone, M. B., M. Nerenberg, P. Southern, J. Price, H. Lewicki. 1991. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65:319.[Medline]
  18. Kagi, D., B. Odermatt, P. S. Ohashi, R. M. Zinkernagel, H. Hengartner. 1996. Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J. Exp. Med. 183:2143.[Abstract/Free Full Text]
  19. Moskophidis, D., M. Battegay, M. van den Broek, E. Laine, U. Hoffmann Rohrer, R. M. Zinkernagel. 1995. Role of virus and host variables in virus persistence or immunopathological disease caused by a non-cytolytic virus. J. Gen. Virol. 76:381.[Abstract/Free Full Text]
  20. Leist, T., A. Althage, E. Haenseler, H. Hengartner, R. M. Zinkernagel. 1989. Major histocompatibility complex-linked susceptibility or resistance to disease caused by a noncytopathic virus varies with the disease parameter evaluated. J. Exp. Med. 170:269.[Abstract/Free Full Text]
  21. Kagi, D., B. Ledermann, K. Burki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31.[Medline]
  22. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.[Abstract/Free Full Text]
  23. Gallimore, A., A. Glithero, A. Godkin, A. C. Tissot, A. Pluckthun, T. Elliott, H. Hengartner, R. M. Zinkernagel. 1998. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187:1383.[Abstract/Free Full Text]
  24. Piedrahita, J. A., S. H. Zhang, J. R. Hagaman, P. M. Oliver, N. Maeda. 1992. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA 89:4471.[Abstract/Free Full Text]
  25. Ishibashi, S., M. S. Brown, J. L. Goldstein, R. D. Gerard, R. E. Hammer, J. Herz. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92:883.
  26. Battegay, M., S. Cooper, A. Althage, J. Banziger, H. Hengartner, R. M. Zinkernagel. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J. Virol. Methods 33:191.[Medline]
  27. Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Prospero, H. Waldmann. 1984. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312:548.[Medline]
  28. Ishibashi, S., J. Herz, N. Maeda, J. L. Goldstein, M. S. Brown. 1994. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc. Natl. Acad. Sci. USA 91:4431.[Abstract/Free Full Text]
  29. Muller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918.[Abstract/Free Full Text]
  30. Leist, T. P., M. Eppler, R. M. Zinkernagel. 1989. Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-{gamma} interferon-treated mice. J. Virol. 63:2813.[Abstract/Free Full Text]
  31. Guidotti, L. G., P. Borrow, A. Brown, H. McClary, R. Koch, F. V. Chisari. 1999. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J. Exp. Med. 189:1555.[Abstract/Free Full Text]
  32. Kundig, T. M., M. F. Bachmann, S. Oehen, U. W. Hoffmann, J. J. L. Simard, C. P. Kalberer, H. Pircher, P. S. Ohashi, H. Hengartner, R. M. Zinkernagel. 1996. On the role of antigen in maintaining cytotoxic T-cell memory. Proc. Natl. Acad. Sci. USA 93:9716.[Abstract/Free Full Text]
  33. Ludewig, B., S. Oehen, F. Barchiesi, R. A. Schwendener, H. Hengartner, R. M. Zinkernagel. 1999. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J. Immunol. 163:1839.[Abstract/Free Full Text]
  34. Zimmermann, C., K. Brduscha-Riem, C. Blaser, R. M. Zinkernagel, H. Pircher. 1996. Visualization, characterization, and turnover of CD8+ memory T cells in virus-infected hosts. J. Exp. Med. 183:1367.[Abstract/Free Full Text]
  35. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177.[Medline]
  36. Plump, A. S., H. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. Verstuyft, E. M. Rubin, J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein-E-deficient mice created by homologous recombination in ES cells. Cell 71:343.[Medline]
  37. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468.[Abstract/Free Full Text]
  38. Ishibashi, S., J. L. Goldstein, M. S. Brown, J. Herz, D. K. Burns. 1994. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93:1885.
  39. Breslow, J. L.. 1996. Mouse models of atherosclerosis. Science 272:685.[Abstract]
  40. Fabricant, C. G., J. Fabricant, M. M. Litrenta, C. R. Minick. 1978. Virus-induced atherosclerosis. J. Exp. Med. 148:335.[Abstract/Free Full Text]
  41. Dal Canto, A. J., H. W.4. Virgin. 1999. Animal models of infection-mediated vasculitis. Curr. Opin. Rheumatol. 11:17.[Medline]
  42. Wick, G., G. Schett, A. Amberger, R. Kleindienst, Q. Xu. 1995. Is atherosclerosis and immunologically mediated disease?. Immunol. Today 16:27.[Medline]
  43. Juvonen, T., J. Juvonen, M. J. Savolainen. 1999. Is vasculitis a significant component of atherosclerosis?. Curr. Opin. Rheumatol. 11:3.[Medline]
  44. Petit, J. C.. 1980. Resistance to listeriosis in mice that are deficient in the fifth component of complement. Infect. Immun. 27:61.[Abstract/Free Full Text]
  45. Drevets, D. A., P. J. Leenen, P. A. Campbell. 1993. Complement receptor type 3 (CD11b/CD18) involvement is essential for killing of Listeria monocytogenes by mouse macrophages. J. Immunol. 151:5431.[Abstract]
  46. van den Broek, M. F., U. Muller, S. Huang, R. M. Zinkernagel, M. Aguet. 1995. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148:5.[Medline]
  47. Moskophidis, D., F. Lechner, H. Pircher, R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758.[Medline]
  48. Binder, D., M. F. van den Broek, D. Kagi, H. Bluethmann, J. Fehr, H. Hengartner, R. M. Zinkernagel. 1998. Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+ T cells in persistent infection with lymphocytic choriomeningitis virus. J. Exp. Med. 187:1903.[Abstract/Free Full Text]
  49. Heiniger, H. J., K. T. Brunner, J. C. Cerottini. 1978. Cholesterol is a critical cellular component for T-lymphocyte cytotoxicity. Proc. Natl. Acad. Sci. USA 75:5683.[Abstract/Free Full Text]
  50. Moazed, T. C., C. Kuo, J. T. Grayston, L. A. Campbell. 1997. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J. Infect. Dis. 175:883.[Medline]
  51. Hu, H., G. N. Pierce, G. Zhong. 1999. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J. Clin. Invest. 103:747.[Medline]
  52. Berencsi, K., V. Endresz, D. Klurfeld, L. Kari, D. Kritchevsky, E. Gonczol. 1998. Early atherosclerotic plaques in the aorta following cytomegalovirus infection of mice. Cell Adhes. Commun. 5:39.[Medline]
  53. Persoons, M. C., M. J. Daemen, J. H. Bruning, C. A. Bruggeman. 1994. Active cytomegalovirus infection of arterial smooth muscle cells in immunocompromised rats: a clue to herpesvirus-associated atherogenesis?. Circ. Res. 75:214.[Abstract/Free Full Text]
  54. Presti, R. M., J. L. Pollock, A. J. Dal Canto, A. K. O’Guin, H. W.4. Virgin. 1998. Interferon {gamma} regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J. Exp. Med. 188:577.[Abstract/Free Full Text]
  55. Weck, K. E., A. J. Dal Canto, J. D. Gould, A. K. O’Guin, K. A. Roth, J. E. Saffitz, S. H. Speck, H. W. Virgin. 1997. Murine {gamma}-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-{gamma} responsiveness: a new model for virus-induced vascular disease. Nat. Med. 3:1346.[Medline]
  56. Adam, E., J. L. Melnick, J. L. Probtsfield, B. L. Petrie, J. Burek, K. R. Bailey, C. H. McCollum, M. E. DeBakey. 1987. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 2:291.[Medline]
  57. Hendrix, M. G., M. M. Salimans, C. P. van Boven, C. A. Bruggeman. 1990. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am. J. Pathol. 136:23.[Abstract]
  58. Fabricant, C. G., D. P. Hajjar, C. R. Minick, J. Fabricant. 1981. Herpesvirus infection enhances cholesterol and cholesteryl ester accumulation in cultured arterial smooth muscle cells. Am. J. Pathol. 105:176.[Abstract]
  59. Schaible, U. E., H. L. Collins, S. H. Kaufmann. 1999. Confrontation between intracellular bacteria and the immune system. Adv. Immunol. 71:267.[Medline]
  60. Bellosta, S., R. W. Mahley, D. A. Sanan, J. Murata, D. L. Newland, J. M. Taylor, R. E. Pitas. 1995. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J. Clin. Invest. 96:2170.
  61. Seiler, P., P. Aichele, B. Odermatt, H. Hengartner, R. M. Zinkernagel, R. A. Schwendener. 1997. Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur. J. Immunol. 27:2626.[Medline]
  62. Zhou, X., G. Paulsson, S. Stemme, G. K. Hansson. 1998. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101:1717.[Medline]
  63. Simons, K., E. Ikonen. 1997. Functional rafts in cell membranes. Nature 387:569.[Medline]
  64. Janes, P. W., S. C. Ley, A. I. Magee, P. S. Kabouridis. 2000. The role of lipid rafts in T cell antigen receptor (TCR) signalling. Semin. Immunol. 12:23.[Medline]



This article has been cited by other articles:


Home page
 Circ. Res.Home page
C. M. Matter and M. A. S. Stein
A Dual Role of CD4+ T Cells in Adipose Tissue?
Circ. Res., April 24, 2009; 104(8): 928 - 930.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
N. Ferre, M. Martinez-Clemente, M. Lopez-Parra, A. Gonzalez-Periz, R. Horrillo, A. Planaguma, J. Camps, J. Joven, A. Tres, F. Guardiola, et al.
Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols
Am J Physiol Gastrointest Liver Physiol, March 1, 2009; 296(3): G553 - G562.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
R. R.S. Packard, E. Maganto-Garcia, I. Gotsman, I. Tabas, P. Libby, and A. H. Lichtman
CD11c+ Dendritic Cells Maintain Antigen Processing, Presentation Capabilities, and CD4+ T-Cell Priming Efficacy Under Hypercholesterolemic Conditions Associated With Atherosclerosis
Circ. Res., October 24, 2008; 103(9): 965 - 973.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
G. W. Martens, M. C. Arikan, J. Lee, F. Ren, T. Vallerskog, and H. Kornfeld
Hypercholesterolemia Impairs Immunity to Tuberculosis
Infect. Immun., August 1, 2008; 76(8): 3464 - 3472.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. Krebs, E. Scandella, B. Bolinger, D. Engeler, S. Miller, and B. Ludewig
Chronic Immune Reactivity Against Persisting Microbial Antigen in the Vasculature Exacerbates Atherosclerotic Lesion Formation
Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2206 - 2213.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
A. T. Shamshiev, F. Ampenberger, B. Ernst, L. Rohrer, B. J. Marsland, and M. Kopf
Dyslipidemia inhibits Toll-like receptor-induced activation of CD8{alpha}-negative dendritic cells and protective Th1 type immunity
J. Exp. Med., February 19, 2007; 204(2): 441 - 452.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. N. Han, L. S. Leka, A. H. Lichtenstein, L. M. Ausman, and S. N. Meydani
Effect of a therapeutic lifestyle change diet on immune functions of moderately hypercholesterolemic humans
J. Lipid Res., December 1, 2003; 44(12): 2304 - 2310.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Matthews, B. Schuster, S. Schutze, I. Bussmeyer, A. Ludwig, C. Hundhausen, T. Sadowski, P. Saftig, D. Hartmann, K.-J. Kallen, et al.
Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)
J. Biol. Chem., October 3, 2003; 278(40): 38829 - 38839.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. N. Han, L. S. Leka, A. H. Lichtenstein, L. M. Ausman, E. J. Schaefer, and S. N. Meydani
Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia
J. Lipid Res., March 1, 2002; 43(3): 445 - 452.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ludewig, B.
Right arrow Articles by Zinkernagel, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ludewig, B.
Right arrow Articles by Zinkernagel, R. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS